• Explore /
  • Poster
  • / Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type <i>KRAS</i> exon 2 metastatic colorectal cancer (mCRC).

Prevalence and outcomes of patients (pts) with EGFR S492R ectodomain mutations in ASPECCT: Panitumumab (pmab) vs. cetuximab (cmab) in pts with chemorefractory wild-type KRAS exon 2 metastatic colorectal cancer (mCRC).

Abstract Poster

Authors

Timothy Price

Timothy Jay Price

Queen Elizabeth Hospital, University of Adelaide, Woodville, Australia

Timothy Jay Price , Kathryn Newhall , Marc Peeters , Tae Won Kim , Jin Li , Stefano Cascinu , Paul Ruff , Attili Venkatasatya Suresh , Anne Thomas , Sergei Tjulandin , Michael Boedigheimer , Kathy Zhang , Roger Sidhu , Swaminathan Murugappan

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2015 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

General Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01001377

Citation

J Clin Oncol 33, 2015 (suppl 3; abstr 740)

DOI

10.1200/jco.2015.33.3_suppl.740

Abstract #

740

Poster Bd #

E30

Abstract Disclosures

Similar Posters

First Author: Marc Peeters

First Author: Timothy Jay Price

First Author: Jonathan D Sorah

First Author: Thomas H. Cartwright